Navigation Links
Metabolic protein launches sugar feast that nurtures brain tumors
Date:11/26/2012

HOUSTON - Researchers at The University of Texas MD Anderson Cancer Center have tracked down a cancer-promoting protein's pathway into the cell nucleus and discovered how, once there, it fires up a glucose metabolism pathway on which brain tumors thrive.

They also found a vital spot along the protein's journey that can be attacked with a type of drug not yet deployed against glioblastoma multiforme, the most common and lethal form of brain cancer. Published online by Nature Cell Biology, the paper further illuminates the importance of pyruvate kinase M2 (PKM2) in cancer development and progression.

"PKM2 is very active during infancy, when you want rapid cell growth, and eventually it turns off. Tumor cells turn PKM2 back on - it's overexpressed in many types of cancer," said Zhimin Lu, M.D., Ph.D., the paper's senior author and an associate professor in MD Anderson's Department of Neuro-Oncology.

Lu and colleagues showed earlier this year that PKM2 in the nucleus also activates a variety of genes involved in cell division. The latest paper shows how it triggers aerobic glycolysis, processing glucose into energy, also known as the Warburg effect, upon which many types of solid tumors rely to survive and grow.

"PKM2 must get to the nucleus to activate genes involved in cell proliferation and the Warburg effect," Lu said. "If we can keep it out of the nucleus, we can block both of those cancer-promoting pathways. PKM2 could be an Achilles' heel for cancer."

By pinpointing the complicated steps necessary for PKM2 to penetrate the nucleus, Lu and colleagues found a potentially druggable target that could keep the protein locked in the cell's cytoplasm.

MEK, ERK emerge as targets

The process begins when the epidermal growth factor connects to its receptor on the cell surface. This leads to:

  • Activation of the MEK protein, which in turn activates ERK.

  • ERK sticking a phosphate group to a specific spot on PKM2.

  • Phosphorylation priming PKM2 for a series of steps that culminate in its binding to the protein importin, which lives up to its name by taking PKM2 through the nuclear membrane.

Once in the nucleus, the team showed that PKM2 activates two genes crucial to aerobic glycolysis and another that splices PKM RNA to make even more PKM2.

An experiment applying several kinase-inhibiting drugs to human glioblastoma cell lines showed that only a MEK/ERK inhibitor prevented EGF-induced smuggling of PKM2 into the nucleus. ERK activation then is mandatory for PKM2 to get into the nucleus.

"MEK/ERK inhibitors have not been tried yet in glioblastoma multiforme," Lu said. Phosporylated PKM2 is a potential biomarker to identify patients who are candidates for MEK/ERK inhibitors once those drugs are developed.

MEK inhibitor blocks tumor growth

The researchers also found that the two glycolysis genes activated by PKM2, called GLUT1 and LDHA, are required for glucose consumption and conversion of pyruvate to lactate, crucial factors in the Warburg Effect. Depleting PKM2 in tumor cell lines reduced glucose consumption and lactate production.

In mice, depleting PKM2 blocked the growth of brain tumors. Re-expressing the wild type protein caused tumors to grow. However, re-expression of a PKM2 mutant protein that lost its ability to get into the nucleus failed to promote tumor formation. Experiments in human glioblastoma cell lines showed the same effect.

Injecting the MEK inhibitor selumetinib into tumors inhibited tumor growth, reduced ERK phosphorylation, PKM2 expression and lactate production in mice. In 48 human tumor samples, the team found that activity of EGFR, ERK1/2 and PKM2 were strongly correlated.

Cause of PKM2 overexpression

Lu and colleagues also published a paper in Molecular Cell that revealed a mechanism for overexpression of PKM2 in glioblastoma. They found that EGF receptor activation turns on NF-?B, which leads to a series of events culminating in PKM2 gene activation.

PKM2 levels were measured in tumor samples from 55 glioblastoma patients treated with standard of care surgery, radiation and chemotherapy. The 20 with low PKM2 expression had a median survival of 34.5 months, compared to 13.6 months for the 35 patients with high levels of PKM2.

Level of PKM2 expression in 27 low-grade astrocytomas was about half of the expression found in higher grade glioblastomas.

"In these two papers, we show how PKM2 is overexpressed in tumors, how it gets into the nucleus, that nuclear entry is essential to tumor development, and identified potential drugs and a biomarker that could usefully treat people," Lu said.


'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Related medicine news :

1. Normal triglyceride levels in people of African descent may hinder diagnosis of metabolic syndrome
2. Study: Women not getting enough exercise; at risk of developing metabolic syndrome
3. Mutant Kras drives pancreatic cancer maintenance via metabolic pathways
4. VCU researchers identify changes in cholesterol metabolic pathways
5. Metabolic Cooking Review For Karine Losier and Dave Ruel's Diet And Cookbook Program Released
6. Bees shed light on human sweet perception and metabolic disorders
7. Metabolic protein wields phosphate group to activate cancer-promoting genes
8. Ancestral link places Mexican-Americans at greater risk for metabolic disease
9. New research uncovers diverse metabolic roles for PML tumor suppressor gene
10. Obesity and metabolic syndrome associated with impaired brain function in adolescents
11. Metabolic engineer synthesizes key breast milk ingredient, makes research possible
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Metabolic protein launches sugar feast that nurtures brain tumors
(Date:2/10/2016)... NASHVILLE, Tenn. (PRWEB) , ... February 10, 2016 ... ... by the American Academy of Emergency Medicine , an emergency medicine ... of practice management services . , The American Academy of Emergency Medicine, ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... a master charity program created to assist the local community. Pledging to select ... leaders and nonprofit organizations in the area. Their goal is to bring community ...
(Date:2/10/2016)... FRANCISCO, Calif. (PRWEB) , ... February 10, 2016 , ... ... Best Water Brand. There were three leading bottled water brand owners that topped the ... services that enhance connectivity and optimize conversion. The premier brand was Tibet 5100, a ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Dr. Jessica ... the practice is now accepting new dental patients and families in the North Metro ... dental care services from cleanings to cosmetic dentistry, and all in the most relaxing ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... bring together more than 200 of the country’s top healthcare executives to share ... “The true benefit of the Forum is the provider-centric perspective, experience, expertise and ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... -- Fotona, based in the U.S. and Europe ... Lightwalker dental laser at the upcoming 151 st Midwinter ... in booth #4815. The ST PRO is a full featured ... features of the award winning, industry leading Lightwalker ATS. At an ... be very attractive to many dentists hesitating to incorporate lasers ...
(Date:2/10/2016)... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), today ... and full year ended December 31, 2015. ... transformational year for Vanda with the continued growth of ... of HETLIOZ for Non-24," said Mihael H. Polymeropoulos, M.D., ... our U.S. product portfolio builds on this success and ...
(Date:2/10/2016)... 2016 A new report from business intelligence provider GBI ... the Alzheimer,s disease market will more than double from just under $5 billion ... Growth Rate (CAGR) of 11%. Canada , ... Spain , the UK, and Japan , ... --> Canada , France , ...
Breaking Medicine Technology: